Connect with us


BioNTech warns ‘no data’ to support UK plan to space Covid shots



BioNTech, the German biotech group behind the first approved Covid-19 vaccine, warned there was “no data” to support moves to delay the second dose of the jab with the aim of reaching as many people as possible with limited supplies.

Germany is considering following the UK in delaying second doses of Covid-19 vaccines in the hope of inoculating more people amid growing concern over a new variant of the virus, which emerged in England.

Germany’s health ministry confirmed to the Financial Times that it had asked the country’s vaccination commission “to review and evaluate the available data and studies and to issue a recommendation on this issue”.

The move came after Britain chose to extend the timeline for the second dose of vaccines from BioNTech/Pfizer and Oxford/AstraZeneca from three or four weeks to up to three months.

BioNTech said the trials for the vaccine it developed with US pharmaceutical group Pfizer were based on two doses administered 21 days apart and that this remained the recommended advice.

“[The] safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design,” the Mainz-based company told the Financial Times.

BioNTech’s comments echoed its partner Pfizer, which also called the UK decision into question last week by restating the recommended 21-day period between doses.

Data from the companies’ phase 3 trials, which involved more than 43,000 people in six countries, demonstrated that participants gained partial protection from the vaccine as early as 12 days after the first dose. But the study did not show how long that protection lasted, as participants received their second shot nine days later.

A review in the New England Journal of Medicine, published last month, found that between the first and second doses, the group that received the vaccine had fewer than half the number of infections than the group that received the placebo.

Those results suggest an efficacy rate of 52 per cent after the first dose, which was higher than the protection level required for a Covid-19 vaccine by the US regulator.

The UK’s four chief medical officers, including England’s Chris Whitty, have defended the decision to extend the recommended gap between the first and second dose from 21 days to up to three months.

“We have to ensure that we maximise the number of eligible people who receive the vaccine,” the officials said in a joint statement last week. “Currently the main barrier to this is vaccine availability, a global issue, and this will remain the case for several months.”

The rapid spread of a new mutant strain of Sars-Cov-2 in the UK has encouraged some scientists in other countries to back the UK’s approach.

Akiko Iwasaki, professor of immunobiology at Yale University, said that while she remained a proponent of the two-dose schedule, “given the urgency, we can delay the second dose until more vaccines become available”.

“It was the B.1.1.7 variant transmission rate that did it for me,” Prof Iwasaki said on Twitter, referring to reports that the new strain was at least 50 per cent more transmissible.

Thomas Mertens, the head of Germany’s vaccine committee, told the DPA news agency last week that extending the gap between doses was “definitely worth considering”. The country is also exploring whether it can extract six doses from each vial of the BioNTech/Pfizer vaccine, rather than the five currently recommended by the manufacturers.

Some scientists have warned that extending the interval between first and second doses could increase the risk of vaccine-resistant mutations, if the virus is then transmitted between millions of people who are partially but not fully protected against infection.

“Delay in second dosing may contribute to this risk,” said Deenan Pillay, professor of virology at University College London and a member of Independent Sage, a UK group of scientists who offer an alternative view to the UK government’s official advisers. “But I understand the public health argument for making the first doses a priority, since we are in a complete emergency with our hospitals overwhelmed.”

Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


German regulator steps in as Greensill warns of threat to 50,000 jobs




Germany’s financial watchdog has taken direct oversight of day-to-day operations at Greensill Bank, as the lender’s ailing parent company warned that its loss of $4.6bn of credit insurance could cause a wave of defaults and 50,000 job losses.

BaFin appointed a special representative to oversee Greensill Bank’s activities in recent weeks, according to three people familiar with the matter, as concern mounted about the state of the lender’s balance sheet.

The German-based lender is one part of a group — advised by former UK prime minister David Cameron and backed by SoftBank — that extends from Australia to the UK and is now fighting for its survival.

On Monday night Greensill was denied an injunction by an Australian court after the finance group tried to prevent its insurers pulling coverage.

Greensill’s lawyers said that if the policies covering loans to 40 companies were not renewed, Greensill Bank would be “unable to provide further funding for working capital of Greensill’s clients”, some of whom were “likely to become insolvent, defaulting on their existing facilities”.

In turn that may “trigger further adverse consequences”, putting over 50,000 jobs around the world at risk, including more than 7,000 in Australia, the company’s lawyers told the court.

A judge ruled Greensill had delayed its application “despite the fact that the underwriters’ position was made clear eight months ago” and denied the injunction.

Greensill Capital is locked in talks with Apollo about a potential rescue deal, involving the sale of certain assets and operations. It has also sought protection from Australia’s insolvency regime.

Greensill was dealt a severe blow on Monday when Credit Suisse suspended $10bn of funds linked to the supply-chain finance firm, citing “considerable uncertainties” about the valuation of the funds’ assets. A second Swiss fund manager, GAM, also severed ties on Tuesday. Credit Suisse’s decision came after credit insurance expired, according to people familiar with the matter.

While the bulk of Greensill’s business is based in London, its parent company is registered in the Australian city of Bundaberg, the hometown of its founder Lex Greensill.

In Germany, where Greensill has owned a bank since 2014, BaFin, the financial watchdog, is drawing on a section of the German banking act that entitles the regulator to parachute in a special representative entrusted “with the performance of activities at an institution and assign [them] the requisite powers”.

The regulator has been conducting a special audit of Greensill Bank for the past six months and may soon impose a moratorium on the lender’s operations, these people said.

Concern is growing among regulators about the quality of some of the receivables that Greensill Bank is holding on its balance sheet, two people said. Regulators are also scrutinising the insurance that the lender has said is in place for its receivables.

Greensill Bank has provided much of the funding to GFG Alliance, a sprawling empire controlled by industrialist Sanjeev Gupta.

“There has been an ongoing regulatory audit of the bank since autumn,” said a spokesman for Greensill. “This regulatory audit report has specifically not revealed any malfeasance at the bank. We have constructive ongoing dialogue with all regulators in all jurisdictions where we operate.”

The spokesman added that all of the banks assets are “unequivocally” covered by insurance.

Greensill, a 44-year-old former investment banker, has said that the idea for his company was shaped by his experiences growing up on a watermelon farm in Bundaberg, where his family endured financial hardships when large corporations delayed payments.

Greensill Capital’s main financial product — supply-chain finance — is controversial, however, as critics have said it can be used to disguise mounting corporate borrowings.

Even if an agreement is struck with Apollo, it could still effectively wipe out shareholders such as SoftBank’s Vision Fund, which poured $1.5bn into the firm in 2019. SoftBank’s $100bn technology fund has already substantially written down the value of its stake.

Gupta, a British industrialist who is one of Greensill’s main clients, separately saw an attempt to borrow hundreds of millions of dollars from Canadian asset manager Brookfield collapse.

Executives at Credit Suisse are particularly nervous about the supply-chain finance funds’ exposure to Gupta’s opaque web of ageing industrial assets, said people familiar with the matter.

The FT reported earlier on Tuesday that Credit Suisse has larger and broader exposure to Greensill Capital than previously known, with a $160m loan, according to two people familiar with the matter.

Additional reporting by Laurence Fletcher and Kaye Wiggins in London

Source link

Continue Reading


FT 1000: Europe’s Fastest Growing Companies




The latest annual ranking of businesses by revenue growth. Explore the 2021 list here — the full report including in-depth analysis and case studies will be published on March 22

Source link

Continue Reading


EU plans digital vaccine passports to boost travel




Brussels is to propose a personal electronic coronavirus vaccination certificate in an effort to boost travel around the EU once the bloc’s sluggish immunisation drive gathers pace.

Ursula von der Leyen, European Commission president, said on Monday the planned “Digital Green Pass” would provide proof of inoculation, test results of those not yet jabbed, and information on the holder’s recovery if they had previously had the disease.

“The Digital Green Pass should facilitate Europeans‘ lives,” von der Leyen wrote in a tweet on Monday. “The aim is to gradually enable them to move safely in the European Union or abroad — for work or tourism.”

The plan, expected to be outlined this month, is a response to a push by Greece and some other EU member states to introduce EU “vaccination passports” to help revive the region’s devastated travel industry and wider economy. 

But the commission’s proposed measures will be closely scrutinised over concerns including privacy, the chance that even inoculated people can spread Covid-19, and possible discrimination against those who have not had the opportunity to be immunised.

In an immediate sign of potential opposition, Sophie Wilmès, Belgium’s foreign minister, raised concerns about the plan. She said that while the idea of a standardised European digital document to gather the details outlined by von der Leyen was a good one, the decision to style it a “pass” was “confusing”. 

“For Belgium, there is no question of linking vaccination to the freedom of movement around Europe,” Wilmès wrote in a tweet. “Respect for the principle of non-discrimination is more fundamental than ever since vaccination is not compulsory and access to the vaccine is not yet generalised.”

The travel sector tentatively welcomed the news of Europe-wide vaccine certification as a way to rebuild confidence ahead of the crucial summer season, but warned that regular and rapid testing was a more efficient and immediate way to allow the industry to restart.

Fritz Joussen, chief executive of Tui, Europe’s largest tour operator, said “with a uniform EU certificate, politicians can now create an important basis for summer travel”. But he added that testing remained “the second important building block for safe holidays” while large numbers of Europeans awaited a jab.

Marco Corradino, chief executive of online travel agent, said he feared the infrastructure needed would not be ready in time for the summer season: “It will not work . . . at EU level because it is too complicated and would not be in place by June.”

He suggested that bilateral deals, such as the one agreed between Greece and Israel in February to allow vaccinated citizens to travel without the need to show a negative test result, had more potential.

Vaccine passport sceptics argue it would be unfair to restrict people’s travel rights simply because they are still waiting for their turn to be jabbed. 

Gloria Guevara, CEO of the World Travel and Tourism Council, said it was important not to discriminate against less advanced countries and younger travellers, or those who simply cannot or choose not to be vaccinated. “Future travel is about a combination of measures such as comprehensive testing, mask-wearing, enhanced health and hygiene protocols as well as digital passes for specific journeys,” she added.

A European Commission target to vaccinate 70 per cent of the bloc’s 446m residents by September means many people are likely to go through summer unimmunised.

While some countries around the world have long required visitors to be vaccinated against infectious diseases such as yellow fever, a crucial difference with coronavirus is that those inoculations are available to travellers on demand. 

Questions also remain about the risk of people who have already been vaccinated passing on coronavirus if they contract the disease.


Source link

Continue Reading